Allorestricted peptide-specific t cells
AssigneeHelmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
InventorsAngela Krackhardt, Ingrid Schuster, Dirk Busch
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1/KW13 and being capable of inducing peptide specific killing of a target cell. The present invention is further directed to one antigenic peptides derived from tumor-associated antigen FMNL1/KW13, to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of FMNL1/KW13.
Claims11
An isolated antigen-specific T cell comprising a T cell receptor (TCR) that specifically recognizes an antigenic peptide bound to human leukocyte antigen A2 (HLA-A2), wherein the antigenic peptide has the amino acid sequence of SEQ ID NO:
- 2.
A pharmaceutical composition comprising the isolated antigen-specific T cell of claim 6 and a pharmaceutically acceptable carrier.
A T cell or peripheral blood mononuclear cell (PBMC) comprising an expression construct encoding a T cell receptor (TCR), wherein the TCR comprises a CDR3 amino acid sequence selected from the group consisting of SEQ ID NOs:
- 9-14.
Dependencies are inferred from the claim text.